Non-Hodgkin Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Non-Hodgkin Lymphoma Pipeline Drugs Market Report Overview

Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. Symptoms may include night sweats, fever and chills that come and go, itching, putting pressure on the windpipe (trachea) or other airways, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if cancer affects the brain. Treatment includes surgery, radiation therapy, and chemotherapy.

The NHL pipeline drugs market research report provides comprehensive information on the therapeutics under development for NHL, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for the NHL and features dormant and discontinued projects.

NHL Pipeline Drugs Market Segmentation by Targets

Some of the targets of the NHL pipeline drugs market are Cells Expressing B Lymphocyte Antigen CD19, Cells Expressing B Lymphocyte Antigen CD20, Tyrosine Protein Kinase BTK, Cells Expressing B Cell Receptor CD22, CD3, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, Programmed Cell Death Protein 1, Leukocyte Surface Antigen CD47, Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8, and others.

NHL Pipeline Drugs Market Analysis, by Targets

NHL Pipeline Drugs Market Analysis, by Targets

For more NHL pipeline drugs market target insights, download a free report sample

NHL Pipeline Drugs Market Segmentation by Mechanisms of Action

Some of the key mechanisms of action of the NHL pipeline drugs market are Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Tyrosine Protein Kinase BTK Inhibitor, Cytotoxic To Cells Expressing B Cell Receptor CD22, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, CD3 Agonist, Programmed Cell Death Protein 1 Antagonist, Leukocyte Surface Antigen CD47 Inhibitor, and others.

NHL Pipeline Drugs Market Analysis, by Mechanisms of Action

NHL Pipeline Drugs Market Analysis, by Mechanisms of Action

For more mechanisms of action insights into the NHL pipeline drugs market, download a free report sample

NHL Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the NHL pipeline drugs market are intravenous, oral, parenteral, subcutaneous, intratumor, intravenous drip, topical, intramuscular, and others.

NHL Pipeline Drugs Market Analysis, by Routes of Administration

NHL Pipeline Drugs Market Analysis, by Routes of Administration

For more routes of administration insights into the NHL pipeline drugs market, download a free report sample

NHL Pipeline Drugs Market Segmentation by Molecule Types

The molecule types in the NHL pipeline drugs market are Small Molecule, Gene-Modified Cell Therapy, Monoclonal Antibody, Monoclonal Antibody Conjugated, Cell Therapy, Fusion Protein, Synthetic Peptide, Recombinant Protein, and others.

NHL Pipeline Drugs Market Analysis, by Molecule Types

NHL Pipeline Drugs Market Analysis, by Molecule Types

For more molecule type insights into the NHL pipeline drugs market, download a free report sample

NHL Pipeline Drugs Market - Competitive Landscape

Some of the key companies in the NHL pipeline drugs market are Bristol-Myers Squibb Co, AstraZeneca Plc, F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc, Gracell Biotechnologies Inc, Merck & Co Inc, AbbVie Inc, BeiGene Ltd, and others.

NHL Pipeline Drugs Market Analysis, by Companies

NHL Pipeline Drugs Market Analysis, by Companies

To know more about the NHL pipeline drugs market companies, download a free report sample

NHL Pipeline Drugs Market Report Overview

Key Targets Cells Expressing B Lymphocyte Antigen CD19, Cells Expressing B Lymphocyte Antigen CD20, Tyrosine Protein Kinase BTK, Cells Expressing B Cell Receptor CD22, CD3, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, Programmed Cell Death Protein 1, Leukocyte Surface Antigen CD47, Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8, and Others
Key Mechanisms of Action Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Tyrosine Protein Kinase BTK Inhibitor, Cytotoxic To Cells Expressing B Cell Receptor CD22, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, CD3 Agonist, Programmed Cell Death Protein 1 Antagonist, Leukocyte Surface Antigen CD47 Inhibitor, and Others
Key Routes of Administration Intravenous, Oral, Parenteral, Subcutaneous, Intratumor, Intravenous Drip, Topical, Intramuscular, and Others
Key Molecule Types Small Molecule, Gene-Modified Cell Therapy, Monoclonal Antibody, Monoclonal Antibody Conjugated, Cell Therapy, Fusion Protein, Synthetic Peptide, Recombinant Protein, and Others
Key Companies Bristol-Myers Squibb Co, AstraZeneca Plc, F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc, Gracell Biotechnologies Inc, Merck & Co Inc, AbbVie Inc, BeiGene Ltd, and Others

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of NHL.
  • The pipeline guide reviews pipeline therapeutics for NHL by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in NHL therapeutics and enlists NHL in their major and minor projects.
  • The pipeline guide evaluates NHL therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates NHL in the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for NHL

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for NHL.
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding the NHL pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.

2Seventy Bio Inc
3SBio Inc
4SC AG
A. Menarini Industrie Farmaceutiche Riunite Srl
AB Science SA
AbbVie Inc
Abclon Inc
Abologix Sarl
Acepodia Inc
Acerta Pharma BV
Achelois Cell Therapy
Actinium Pharmaceuticals Inc
Actinobac Biomed Inc
Adagene Suzhou Ltd
ADC Therapeutics SA
Adicet Bio Inc
Adienne Pharma & Biotech SA
Adlai Nortye Biopharma Co Ltd
Advenchen Laboratories LLC
Affimed GmbH
AI Therapeutics Inc
Akeso Inc
AKSO Biopharmaceutical Inc
Alaunos Therapeutics Inc
Aleta Biotherapeutics Inc
Alexion Pharmaceuticals Inc
Alfasigma SpA
Allogene Therapeutics Inc
Alphamab Oncology
Alpine Immune Sciences Inc
Altamira Therapeutics Ltd
ALX Oncology Holdings Inc
Amgen Inc
Angimmune LLC
Angiocrine Bioscience Inc
Anhorn Medicines Co Ltd
Anhui Anke Biotechnology (Group) Co Ltd
Antengene Corp Ltd
AP Biosciences Inc
Apollomics Inc
Apotex Inc
Arcus Biosciences Inc
Ardan Pharma
Argenx SE
Arvinas Inc
Ascentage Pharma Group Inc
Ascentage Pharma Group International
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Asylia Therapeutics Inc
Atara Biotherapeutics Inc
Athenex Inc
Aurigene Discovery Technologies Ltd
Autolus Therapeutics Plc
Avalon GloboCare Corp
Avesthagen Ltd
Avipep Pty Ltd
AVM Biotechnology LLC
Avvinity Therapeutics Ltd
Axter Therapeutics Ltd
AzarGen Biotechnologies (Pty) Ltd
BAKX Therapeutics Inc
Bantam Pharmaceutical LLC
Bayer AG
BeiGene Ltd
Beijing Cytoheal Biotech Co Ltd
Beijing Gaobo Biotechnology Co Ltd
Beijing GD Initiative Cell Therapy Technology Co Ltd
Beijing Immunochina Pharmaceuticals Co Ltd
Beijing Jingda Biotechnology Co Ltd
Beijing Luzhu Biotechnology Co Ltd
Beijing Mabworks Biotech Co Ltd
Bellicum Pharmaceuticals Inc
Betta Pharmaceuticals Co Ltd
Bio-Path Holdings Inc
Bio-Thera Solutions Ltd
BioCurate Pty Ltd
BioEclipse Therapeutics Inc
Biogen Inc
BioIntegrator
BioInvent International AB
BioLineRx Ltd
Biomea Fusion Inc
BioNTech SE
BioPact Ventures LLC
BioTheryX Inc
BioXpress Therapeutics SA
Bivictrix Therapeutics PLC
Boehringer Ingelheim International GmbH
Boryung Pharmaceutical Co Ltd
Boryung ViGenCell Inc
Bristol-Myers Squibb Co
C4 Therapeutics Inc
Calithera Biosciences Inc
Caribou Biosciences Inc
Carna Biosciences Inc
Carrick Therapeutics Ltd
CARsgen Therapeutics Ltd
Cartherics Pty Ltd
Catalent Inc
Catapult Therapeutics BV
Celdara Medical LLC
Cell Source Inc
Cell>Point LLC
CellCentric Ltd
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Cellectis SA
Cellenkos Inc
Celleron Therapeutics Ltd
Cellestia Biotech AG
Celltrion Inc
Cellular Biomedicine Group Inc
Celularity Inc
Centaurus Biopharma Co Ltd
Centrose LLC
Centrymed Pharmaceutical Inc
Century Therapeutics Inc
Ceptur Therapeutics Inc
CerRx Inc
CGeneTech (Suzhou China) Co Ltd
Changzhou Qianhong Bio-Pharma Co Ltd
Cheetah Cell Therapeutics Co Ltd
Chengdu Brilliant Pharmaceutical Co Ltd
Chengdu Hyperway Pharmaceutical Co Ltd
Chengdu Jinrui Foundation Biotechnology Co Ltd
Chengdu Zenitar Biomedical Technology Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chimagen Biosciences Ltd
Chimeric Therapeutics Ltd
China Immunotech Co Ltd
Chineo Med Beijing Co Ltd
CHO Pharma Inc
Chongqing Precision Biotech Co Ltd
Chugai Pharmaceutical Co Ltd
Cielo Therapeutics Inc
Clayton Biotechnologies Inc
Clevexel Pharma SA
Clonz Biotech Pvt Ltd
Codiak BioSciences Inc
CoImmune Inc
Conjupro Biotherapeutics Inc
Cornerstone Pharmaceuticals Inc
Corvus Pharmaceuticals Inc
Cothera Bioscience Pty Ltd
CRISPR Therapeutics AG
CrystalGenomics Inc
CSL Ltd
CSPC Pharmaceutical Group Ltd
CStone Pharmaceuticals Co Ltd
CTI BioPharma Corp
Cullinan Oncology Inc
Curis Inc
Curocell Inc
Curon Biopharmaceutical Ltd
Cyclacel Pharmaceuticals Inc
Cyteir Therapeutics Inc
CytomX Therapeutics Inc
Daiichi Sankyo Co Ltd
Daysai Biopharmaceuticals Inc
Dayton Therapeutics AG
Debiopharm International SA
DeepCure Inc
DEKK-TEC Inc
Denovo Biopharma LLC
Dialectic Therapeutics Inc
Dizal (Jiangsu) Pharmaceutical Co Ltd
Dr. Reddy's Laboratories Ltd
Dren Bio Inc
Duet Therapeutics Inc
EdiGene Inc
eFFECTOR Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
Elicera Therapeutics AB
Emergent BioSolutions Inc
Emmaus Life Sciences Inc
Enterome Bioscience SA
Epidestiny Inc
Epizyme Inc
Equillium Inc
Esanex Inc
Estrella Biopharma Inc
Eternity Bioscience Inc
Eucure (Beijing) Biopharma Co Ltd
Eureka Therapeutics Inc
Eutilex Co Ltd
Evopoint Bioscience Co Ltd
Evotec SE
Excelmab Inc
Exelixis Inc
Exinda Therapeutics LLC
F-star Therapeutics Inc
F. Hoffmann-La Roche Ltd
FamiCordTx SA
Fate Therapeutics Inc
Fochon Pharmaceutical Ltd
Fosun Kite Biotechnology Co Ltd
Fresh Tracks Therapeutics Inc
Fujifilm Holdings Corp
FutureGen Biopharm Technology Co Ltd
Galapagos NV
Galderma SA
Gamida Cell Ltd
Geneius Biotechnology Inc
Genentech USA Inc
Geneos Therapeutics Inc
GeneScience Pharmaceuticals Co Ltd
Genexine Inc
Genmab AS
Genor BioPharma Co Ltd
Genosco Inc
Gibson Oncology LLC
Gilead Sciences Inc
Gossamer Bio Inc
Gracell Biotechnologies Inc
Green Cross LabCell Corp
Greenfire Bio LLC
Grupo Ferrer Internacional SA
GSK plc
GT Biopharma Inc
Guangdong East Sunshine Pharmaceutical Co Ltd
Guangdong Zhongsheng Pharmaceutical Co Ltd
Guangzhou Bairui Biomedical Technology Co Ltd
Guangzhou BeBetter Medicine Technology Co Ltd
Guangzhou Bio-gene Technology Co Ltd
Guangzhou Sinogen Pharmaceutical Co Ltd
H3 Biomedicine Inc
Haisco Pharmaceutical Group Co Ltd
Hangzhou Hezheng Pharmaceutical Co Ltd
Hangzhou Minsheng Pharmaceutical Group Co Ltd
Hangzhou Rongu Biotechnology Co Ltd
Hangzhou Sumgen Biotech Co Ltd
Hangzhou Zenshine Pharmaceuticals Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Hebei Senlang Biotechnology Co Ltd
HEC Pharma Co Ltd
Hefei Hankemab Biotechnology Co Ltd
Heidelberg Pharma AG
Helocyte Biosciences Inc
Helsinn Group
Hibercell Inc
HK inno.N Corp
HRAIN Biotechnology Co Ltd
Hualan Biological Engineering Inc
Hunan Siweikang Therapeutics Ltd
Hutchison MediPharma Ltd
I-Mab
iBio Inc
iCell Gene Therapeutics LLC
IDP Discovery Pharma SL
IGM Biosciences Inc
Iksuda Therapeutics Ltd
ImCheck Therapeutics SAS
Immune Cell Inc
ImmuneCyte Inc
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
ImmuneTarget Inc
Immunitas Therapeutics Inc
ImmunityBio Inc
ImmunoAct Pvt Ltd
ImmunoGen Inc
Immunomet Therapeutics Inc
Immunotech Biopharm Ltd
Impetis Biosciences Ltd
IMV Inc
Inatherys
Incyte Corp
Indaptus Therapeutics Inc
Inflection Biosciences Ltd
Innate Pharma SA
InnoBation Bio
InnoCare Pharma Ltd
Innovative Cellular Therapeutics Co Ltd
Innovent Biologics Inc
Invion Ltd
IO Biotech Inc
iOnctura SA
Ionis Pharmaceuticals Inc
Iterion Therapeutics Inc
Japan Tobacco Inc
Jazz Pharmaceuticals Plc
Jiangsu Carephar Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Maidu Drug Research and Development Co Ltd
Jing Medicine Technology Shanghai Ltd
JN Biosciences LLC
Johnson & Johnson
Jubilant Therapeutics Inc
Juventas Cell Therapy Ltd
JW Cayman Therapeutics Co Ltd
KAHR medical Ltd
Kainos Medicine Inc
Kangpu Biopharmaceuticals Ltd
Kartos Therapeutics Inc
Karus Therapeutics Ltd
Karyopharm Therapeutics Inc
Kecellitics Biotech Co Ltd
Kesios Therapeutics Ltd
Kezar Life Sciences Inc
Kiniksa Pharmaceuticals Ltd
Kiromic BioPharma Inc
Kite Pharma Inc
Klyss Biotech Inc
Komipharm International Co Ltd
Kronos Bio Inc
Kymera Therapeutics Inc
Kyowa Kirin Co Ltd
Lantern Pharma Inc
Lanzhou Institute of Biological Products Co Ltd
Legend Biotech Corp
LegoChem Biosciences Inc
Lepton Pharmaceuticals Ltd
Lepu Biopharma Co Ltd
Les Laboratoires Servier SAS
Light Chain Bioscience
LintonPharm Co Ltd
Livzon Pharmaceutical Group Co Ltd
Loxo Oncology Inc
LTZ Therapeutics Inc
Luminary Therapeutics Inc
Lupin Ltd
Lyvgen Biopharma Ltd
Mabion SA
Mablink Bioscience
Machavert Pharmaceuticals LLC
MacroGenics Inc
ManysmarT Therapeutics Inc
Marino Biotechnology Co Ltd
Marker Therapeutics Inc
Meabco AS
MedC Biopharma Ltd
Medinet Co Ltd
MediSix Therapeutics Pte Ltd
Meditope Biosciences Inc
Medivir AB
MedPacto Inc
MEI Pharma Inc
MENTRIK Biotech LLC
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Miltenyi Biomedicine GmbH
Minghui Pharmaceutical (Shanghai) Co Ltd
MiNK Therapeutics Inc
Mirati Therapeutics Inc
MiRecule Inc
Moderna Inc
Molecular Templates Inc
Moleculin Biotech Inc
Monte Rosa Therapeutics Inc
Morphiex Biotherapeutics Inc
MorphoSys AG
Multitude therapeutics Inc
Mustang Bio Inc
Myeloid Therapeutics Inc
Nanjing Aimeifei Biomedical Technology Co Ltd
Nanjing Bioheng Biotech Co Ltd
Nanjing CART Medical Technology Co Ltd
Nanjing Iaso Biotherapeutics Co Ltd
Nanjing KAEDI Biotech Inc
Nanjing Sanhome Pharmaceutical Co Ltd
Nanjing Yoko Pharmaceutical Co Ltd
Nanoligent SL
Navrogen Inc
Nektar Therapeutics
Neoleukin Therapeutics Inc
Neonc Technologies Inc
Neumedicines Inc
Newave Pharmaceutical Inc
NewBio Therapeutics Inc
Nichi-Iko Pharmaceutical Co Ltd
Ningbo Wenda Pharmaceutical Technology Co Ltd
Nkarta Inc
Nordic Nanovector ASA
Northlake International LLC
NovalGen Ltd
Novartis AG
Numab Therapeutics AG
Nurix Therapeutics Inc
Nutcracker Therapeutics Inc
Nuvalent Inc
Onco Therapies Inc
Onconova Therapeutics Inc
Oncopeptides AB
OncoTartis Inc
Oncovir Inc
Oncternal Therapeutics
OnKure Inc
Ono Pharmaceutical Co Ltd
Orano Med LLC
Orca Biosystems Inc
ORIC Pharmaceuticals Inc
Otsuka Pharmaceutical Co Ltd
Oxcia AB
Oxford BioTherapeutics Ltd
Pacylex Pharmaceuticals Inc
Pell Bio-Med Technology Co Ltd
PeproMene Bio Inc
PersonGen BioTherapeutics (Suzhou) Co Ltd
Pfizer Inc
Pharmapraxis
Philogen SpA
PIQUR Therapeutics AG
Plexxikon Inc
Precigen Inc
Precision Biosciences Inc
Prelude Therapeutics Inc
Prescient Therapeutics Ltd
ProfoundBio Suzhou Co Ltd
Propanc Biopharma Inc
Protheragen Inc
Qilu Pharmaceutical Co Ltd
Qilu Puget Sound Biotherapeutics Corp
QLSF Biotherapeutics Inc
Quimatryx SL
Ranok Therapeutics Co Ltd
RAPT Therapeutics Inc
Refuge Biotechnologies Inc
Regenacy Pharmaceuticals LLC
Regeneron Pharmaceuticals Inc
Remd Biotherapeutics Inc
Repare Therapeutics Inc
Rescue Therapeutics Inc
Respiratorius AB
Rhizen Pharmaceuticals SA
Ribon Therapeutics Inc
Rock Immune LLC
Ryvu Therapeutics SA
SA Science Inc
Sana Biotechnology Inc
Sangamo Therapeutics Inc
Sano Chemicals Inc
Sanofi
Sareum Holdings Plc
Schrodinger Inc
SciTech Development LLC
Score Pharma Inc
Seagen Inc
Secura Bio Inc
selectION Inc
SELLAS Life Sciences Group Inc
Senhwa Biosciences Inc
Sentinel Oncology Ltd
Serb SAS
Shandong New Time Pharmaceutical Co Ltd
Shandong Qidu Pharmaceutical Co Ltd
Shanghai Bioray Laboratory Inc
Shanghai Cell Therapy Group Co
Shanghai First Song Therapeutics Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai GeneChem Co Ltd
Shanghai Haihe Biopharma Co Ltd
Shanghai Haiyan Pharmaceutical Technology Co Ltd
Shanghai Henlius Biotech Inc
Shanghai Institute of Biological Products Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai Longyao Biotechnology Co Ltd
Shanghai Meizer Pharmaceuticals Co Ltd
Shanghai Miracogen Inc
Shanghai Novamab Biopharmaceuticals Co Ltd
Shanghai Pharmaceutical Group Co Ltd
Shanghai Pharmaceuticals Holding Co Ltd
Shanghai Simnova Biotechnology Co Ltd
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Shanghai YaKe Biotechnology Co Ltd
Shanghai Yingli Pharmaceutical Co Ltd
Shattuck Labs Inc
Shengke Pharmaceuticals (Jiangsu) Ltd
Shennong Biotech Inc
Shenogen Pharma Group Ltd
Shenzhen BinDeBio Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Shenzhen Salubris Pharmaceuticals Co Ltd
Shenzhen Targetrx Inc
Shouyao Holding Co Ltd
Sian Wuhan Medical Technology Co Ltd
SideROS
SignalRx Pharmaceuticals Inc
Simcere Pharmaceutical Group Ltd
Sino Biopharmaceutical Ltd
SinoMab Bioscience Ltd
SIRPant Immunotherapeutics Inc
Solasia Pharma KK
Soligenix Inc
Sonoval LLC
Sorrento Therapeutics Inc
SpecificiT Pharma Inc
Spectrum Pharmaceuticals Inc
Step Pharma
StingInn LLC
SumiQ Therapeutics BV
Shenghe (China) Biopharmaceutical Co Ltd
Sunnycell Therapeutics Ltd
Supratek Pharma Inc
Sutro Biopharma Inc
Suzhou Dingfu Target Biotechnology Co Ltd
Suzhou Fundamenta Therapeutics Co Ltd
Suzhou JiSheng Pharmaceutical Co Ltd
Suzhou Maximum Bio-tech Co Ltd
Syncopation Life Sciences Inc
Syros Pharmaceuticals Inc
Systimmune Inc
Tachyon Therapeutics Inc
Tacitus Therapeutics Inc
Taiwan Liposome Co Ltd
Takara Bio Inc
Takeda Pharmaceutical Co Ltd
Tango Therapeutics Inc
Tayu Huaxia Biotech Medical Group Co Ltd
TC BioPharm Ltd
TCR Cure Biopharma Technology Co Ltd
TCR2 Therapeutics Inc
Telios Pharma Inc
Tessa Therapeutics Ltd
Tiannuojiancheng Pharma
Tianweiyuan and Biomedicine Shanghai Co Ltd
Timmune Biotech Inc
TOT Biopharm Co Ltd
Transgene Biotek Ltd
Transgene SA
TransThera Sciences (Nanjing) Inc
Triphase Accelerator Corp
Truvitech LLC
Tubulis GmbH
Turning Point Therapeutics Inc
Tyme Inc
Ubix Therapeutics Inc
United BioPharma Inc
UWELL Biopharma Inc
Verismo Therapeutics
Vidac Pharma
Vincerx Pharma Inc
Viracta Therapeutics Inc
Viridian Therapeutics Inc
Vivolux AB
VM Discovery Inc
Vyriad Inc
Waterstone Hanxbio Pty Ltd
Wellington Zhaotai Therapies Ltd
Wigen Biomedicine Technology (Shanghai) Co Ltd
Wugen Inc
Wuhan Bio-Raid Biotechnology Co Ltd
Wyze Biotech Co Ltd
X4 Pharmaceuticals Inc
Xcovery Holding Co LLC
XEME BioPharma Inc
Xencor Inc
Xenetic Biosciences Inc
Xi'An Yufan Biotechnology Co Ltd
Xiconic Pharmaceuticals LLC
Xynomic Pharmaceuticals Holdings Inc
Xyphos Biosciences Inc
Zentalis Pharmaceuticals Inc
Zhejiang Borui Biopharmaceutical Co Ltd
Zhejiang DTRM Biopharma LLC
Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang Landun Pharmaceutical Co Ltd
Zhejiang Longchuan Biomedical Technology Co Ltd
Zhejiang Teruisi Pharmaceutical Co Ltd
Zhengda Tianqing Pharmaceutical Group Co Ltd
Zhuobo Yong Ji (Shanghai) Biological Pharmaceutical Co Ltd
Zibo Baiji Changsheng Pharmaceutical Co Ltd
Zylem Biosciences Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Non-Hodgkin Lymphoma – Overview

Non-Hodgkin Lymphoma – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Non-Hodgkin Lymphoma – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Non-Hodgkin Lymphoma – Companies Involved in Therapeutics Development

Non-Hodgkin Lymphoma – Drug Profiles

Non-Hodgkin Lymphoma – Dormant Projects

Non-Hodgkin Lymphoma – Discontinued Products

Non-Hodgkin Lymphoma – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Non-Hodgkin Lymphoma, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Non-Hodgkin Lymphoma – Dormant Projects, 2022

Non-Hodgkin Lymphoma – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Non-Hodgkin Lymphoma, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

  • What are the key targets of the NHL pipeline drugs market?

    Some of the targets of the NHL pipeline drugs market are Cells Expressing B Lymphocyte Antigen CD19, Cells Expressing B Lymphocyte Antigen CD20, Tyrosine Protein Kinase BTK, Cells Expressing B Cell Receptor CD22, CD3, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, Programmed Cell Death Protein 1, Leukocyte Surface Antigen CD47, Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8, and others.

  • What are the key mechanisms of action in the NHL pipeline drugs market?

    Some of the mechanisms of action of the NHL pipeline drugs market are Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Tyrosine Protein Kinase BTK Inhibitor, Cytotoxic To Cells Expressing B Cell Receptor CD22, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, CD3 Agonist, Programmed Cell Death Protein 1 Antagonist, Leukocyte Surface Antigen CD47 Inhibitor, and others.

  • What are the key routes of administration in the NHL pipeline drugs market?

    The key routes of administration in the NHL pipeline drugs market are intravenous, oral, parenteral, subcutaneous, intratumor, intravenous drip, topical, intramuscular, and others.

  • What are the key molecule types in the NHL pipeline drugs market?

    The molecule types in the NHL pipeline drugs market are Small Molecule, Gene-Modified Cell Therapy, Monoclonal Antibody, Monoclonal Antibody Conjugated, Cell Therapy, Fusion Protein, Synthetic Peptide, Recombinant Protein, and others.

  • Which are the leading companies in the NHL pipeline drugs market?

    Some of the key companies in the NHL pipeline drugs market are Bristol-Myers Squibb Co, AstraZeneca Plc, F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc, Gracell Biotechnologies Inc, Merck & Co Inc, AbbVie Inc, BeiGene Ltd, and others.

Non-Hodgkin Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Non-Hodgkin Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Non-Hodgkin Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Non-Hodgkin Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.